Peer-reviewedStability Biologics
Placental allograft vs. flap or full-thickness graft after Mohs surgery
Design: Propensity-matched case-controlSize: 286 Mohs defects
Compared with flap or full-thickness graft repair, placental allograft repair had about 12× lower adjusted odds of infection or reintervention (adjusted OR 11.71) and about 19× lower adjusted odds of poor scar cosmesis or revision (adjusted OR 18.76), with equivalent time to wound closure.
Limits: Observational design. Looks at placental allografts as a class, not AmnioCore specifically.
RetrospectiveStability Biologics
Weekly Amnio Tri-Core application after Mohs micrographic surgery
Design: Multi-site retrospective series, no control armSize: 46 patients, 10 sites
Mean wound volume fell from 2.77 cm³ to 0.35 cm³ (p<0.0001). Mean wound-area reduction was 84.4% (median 91.9%), and mean time to complete healing was 8.5 weeks (median 6 weeks).
Limits: Retrospective and uncontrolled. Healing time varied by site (ear 4.7 wks, forehead 21.4 wks).
White paperNufabrx
Capsaicin-infused compression socks for foot pain and edema
Design: Single-center, active-control, prospective trialSize: 20 enrolled, 16 completed
Over 12 weeks, mean FADI (function) improved from 70.7 to 77.4, and the FAOQ score moved from 56.1 to 50.8, which the author reports as an improvement in quality of life.
Limits: Small sample, not peer-reviewed, conducted to support the product. One participant developed contact dermatitis that resolved.
Manufacturer studyPush Patch
KPV + NAD+ iontophoresis and hs-CRP
Design: Internal human studySize: 120 subjects
Push Patch reports an 82.8% mean reduction in hs-CRP within seven days with NAD+ alone, and a 94% mean reduction with the KPV + NAD+ formulation.
Limits: Internal study reported by the manufacturer. Not peer-reviewed; full methods not published in the summary.
Manufacturer studyPush Patch
30-day NAD+ 1300 mg patch and mitochondrial efficiency
Design: Internal 30-day human study (MeScreen)Size: 30
Repeated 12-hour NAD+ 1,300 mg applications were reported to produce statistically significant gains in mitochondrial efficiency by days 15 and 30.
Limits: Internal study reported by the manufacturer. Surrogate biomarkers only; not peer-reviewed.
Bench / 510(k)RegenOMedix
MedGeneRx HP15 510(k) equivalence testing
Design: Device equivalence study (mean results)Size: Not stated
Platelet concentration factor was 4.1–4.5× baseline at 0 hours and 4.5–4.8× at 1 hour, with 61% platelet recovery at 1 hour, RBC 0.01, and pH 7.5.
Limits: Lab performance data, not clinical outcomes. Sample size not stated on the sales sheet.
Case notesVitaCell Bio Global
Physician case summaries: VitaCell and Cytocell
Design: Uncontrolled case summaries from one physicianSize: 3 patients
Angelo A. Caprio, MD, PhD, shared three musculoskeletal case summaries from his practice. They're available to licensed providers on request.
Limits: Anecdotal, uncontrolled, and not peer-reviewed. Not evidence of efficacy.
Case notesRegenOMedix
South Florida chiropractic clinic practice report: PulseWave MiniWave radial ESWT
Design: Single-practice implementation report (Dr. David L., DC)Size: 1 chiropractic clinic (8 initial cash-pay patients to recoup cost)
A South Florida chiropractic practice treating lower back, rotator cuff, and neck pain added a PulseWave MiniWave radial ESWT system (under $9,000), priced sessions at $250 with a complimentary first treatment for existing patients and local gyms/tennis clubs, recouped the machine cost in 3 months on 8 new patients, and reported doubling orthopedic revenue within 8 months.
Limits: Manufacturer-published single-practice case study, not a controlled clinical trial. Revenue and payback depend on local cash pricing, patient volume, and clinic execution.
